Skip to content

Efficacy and Safety of Different Doses of Midazolam for 24-Hour Continuous Sedation in Pre-Eclamptic Women Undergoing Cesarean Section

Efficacy and Safety of Different Doses of Midazolam for 24-Hour Continuous Sedation in Pre-Eclamptic Women Undergoing Cesarean Section

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500114682
Enrollment
Unknown
Registered
2025-12-16
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia

Interventions

Group D:Intravenous midazolam 0.03 mg/kg
Group B:Intravenous midazolam 0.01mg/kg
Group A:Intravenous midazolam 0 mg/kg
Group C:Intravenous midazolam 0.02mg/kg

Sponsors

Zhuji People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1.A pregnant woman was diagnosed with preeclampsia and needed to undergo an emergency or planned cesarean section; 2.The pregnant woman is between 18 and 40 years old; 3.No history of significant allergy to midazolam or related drugs; 4.Follow the doctor's advice, have good compliance and no communication barriers; 5.No history of mental illness or substance abuse; 6.Obtain the informed consent form signed by the patient or their family;

Exclusion criteria

Exclusion criteria: 1.Other ongoing drug treatments, drugs that interact with midazolam; 2.Suffering from other serious diseases, such as lesions of vital organs like the heart, liver and kidneys; 3.Having participated in other clinical trials or studies, it may affect the independence and results of this study; 4.Have coagulopathy or other blood disease;

Design outcomes

Primary

MeasureTime frame
The levels of blood oxygen saturation (SPO2), mean arterial pressure (MAP), and heart rate (HR) of the parturient;

Secondary

MeasureTime frame
Visual anxiety assessment score;Sedative effectiveness;The occurrence of postoperative adverse reactions;Fetal heart rate;

Countries

China

Contacts

Public ContactXuan Hongmei

Zhuji People's Hospital

787835646@qq.com+86 575 81782326

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026